Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Non-cash Items (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Non-cash Items over the past 3 years, most recently at $12.3 million for Q4 2025.

  • Quarterly results put Non-cash Items at $12.3 million for Q4 2025, up 1314002.56% from a year ago — trailing twelve months through Dec 2025 was $12.3 million (up 1314002.56% YoY), and the annual figure for FY2025 was $12.3 million, up 1314002.56%.
  • Non-cash Items for Q4 2025 was $12.3 million at Tonix Pharmaceuticals Holding, up from $2686.0 in the prior quarter.
  • Over the last five years, Non-cash Items for TNXP hit a ceiling of $12.6 million in Q1 2023 and a floor of $936.0 in Q4 2024.
  • Median Non-cash Items over the past 3 years was $6.2 million (2024), compared with a mean of $5.7 million.
  • Peak annual rise in Non-cash Items hit 1314002.56% in 2025, while the deepest fall reached 99.96% in 2025.
  • Tonix Pharmaceuticals Holding's Non-cash Items stood at $259991.0 in 2023, then plummeted by 99.64% to $936.0 in 2024, then surged by 1314002.56% to $12.3 million in 2025.
  • The last three reported values for Non-cash Items were $12.3 million (Q4 2025), $2686.0 (Q3 2025), and $2294.0 (Q2 2025) per Business Quant data.